Calidi Biotherapeutics, INC 10-Q quarterly reports

Calidi Biotherapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing operational losses and significant accumulated deficit, leading to substantial doubt about its ability to continue as a going concern.

Calidi Biotherapeutics reports a net loss of $4.1 million for Q1 2026, with a focus on advancing its RedTail platform and securing future funding.

Calidi Biotherapeutics reported a net loss of $16.0 million for the first nine months of 2025, a decrease from the prior year, while significantly increasing its cash position through multiple equity financings.

Calidi Biotherapeutics reported a reduced net loss for the first half of 2025, driven by lower administrative costs, but faces ongoing liquidity challenges and a going concern warning.

Calidi Biotherapeutics announces its Q1 2025 financial results, highlighting ongoing research and development efforts amidst a leadership transition and concerns about its ability to continue as a going concern.

Calidi Biotherapeutics reports a net loss of $5.1 million for Q3 2024, with ongoing concerns about its ability to continue as a going concern.

Calidi Biotherapeutics reports a net loss of $5.8 million for Q2 2024 and $13.0 million for the first half of 2024, while also expressing substantial doubt about its ability to continue as a going concern.

Calidi Biotherapeutics reports a net loss of $7.2 million for the first quarter of 2024, alongside concerns about its ability to continue as a going concern.